Ex-Aegerion CFO lands at Chiasma; Baxter has high hopes for Baxalta;

@FierceBiotech: Novo's liraglutide works in diabetes and obesity. How about NASH? Story | Follow @FierceBiotech

@JohnCFierce: $EBIO down 78%--That's what you call an extinction level event. ELEven | Follow @JohnCFierce

> Mark Fitzpatrick, who resigned as CFO from Aegerion Pharmaceuticals ($AEGR) last week, has taken the same position at Chiasma. More

> Baxter ($BAX) is still on target to spin off its biopharma business by mid-year, the company said, expecting the new company, Baxalta, to post between 6% and 8% sales growth in its first year of independence. News

> Endo ($ENDP) has agreed to acquire Par Pharmaceutical for $8 billion. Story

Medical Device News

@FierceMedDev: ICYMI: Study: Remote monitoring of cardiac device patients results in better survival, less hospitalization. Article | Follow @FierceMedDev

@VarunSaxena2: The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: Endo scoops up Par Pharma for $8B to gain ground in injectables. FiercePharma story | Follow @EmilyWFierce

> Tech industry group IEEE releases software security guidelines for medical devices. More

> Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Article

Pharma News

@FiercePharma: Who are the top 10 advertisers in Big Pharma? Find out here. FiercePharmaMarketing feature | Follow @FiercePharma

@CarlyHFierce: No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. More from FiercePharmaMarketing | Follow @CarlyHFierce

> AstraZeneca, betting on biologics, will build a $285M facility in Sweden. Report

> Endo scoops up Par Pharma for $8B to gain ground in injectables. Article

Pharma Marketing News

> Diabetes app 'One Drop' drops with digerati backing. Article

> AZ bets big on biologics with $285M Swedish facility. Item

> Sanofi seeks the next Teenage Idol in meningitis vaccine campaign. More

> Can pharma + tech wearables be a match made in patient heaven? Story

> No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. Report

Animal Health News

> Iowa biotech firm set to begin testing vaccine against deadly avian flu. Item

> Phibro records strong sales growth despite industry shift from antibiotics. Report

> ImmuCell enjoys spoils of success as demand for calf protector exceeds supply. More

> Jaguar's delayed and downsized IPO garners muted reception on Wall Street. Story

> FDA warns Lilly to stop marketing antibiotic for weight gain in pigs. Article

Biotech IT News

> GenomeDx shares 7 years of cancer testing data with medical center. Item

> Venter's HLI scoops samples from Cleveland Clinic as data-generating drive continues. More

> Allen Institute advances brain-mapping ambitions with cell-type database. Story

> Regeneron lobbying for its database to be the linchpin of Obama's Precision Medicine program. Article

> AstraZeneca dives into genetics of 80,000 samples in search of CV, diabetes insights. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.